Literature DB >> 2748532

Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide.

J C Shah1, J R Chen, D Chow.   

Abstract

Preformulation studies of etoposide, including pH-solubility profile, partition coefficient, pH-stability profile, and in vitro dissolution kinetics, were conducted to identify the responsible factor(s) for the low and erratic oral bioavailability of etoposide. A stability-indicating high-performance liquid chromatographic (HPLC) assay was used for drug monitoring. The equilibrium aqueous solubility of etoposide at 37 degrees C was low, 148.5-167.25 micrograms/ml, and did not vary over the pH range of 2 to 6. The pH-stability profile indicated rapid degradation of etoposide at pH 1.3 and 10, with degradation half-lives of 2.88 and 3.83 hr, respectively, at 25 degrees C. The half-life at pH 7.30 was 27.72 days. Maximum stability at 25 degrees C was reached at pH 5 to 6.15, with half-lives of 63 and 49.5 days, respectively. The intrinsic dissolution rate, determined on a Wood's apparatus, was slow, 0.0094 mg/min/cm2, while the etoposide partition coefficient between n-octanol and water was 9.94. Therefore, etoposide absorption appears to be dissolution rate limited rather than permeation rate limited. The low equilibrium aqueous solubility, slow intrinsic dissolution rate, and chemical instability at pH 1.3 could account for the low oral bioavailability.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2748532     DOI: 10.1023/a:1015935532725

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  PHASE I clinical trial of an oral solution of VP-16-213.

Authors:  N I Nissen; P Dombernowsky; H H Hansen; V Larsen
Journal:  Cancer Treat Rep       Date:  1976-07

2.  A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213.

Authors:  G Falkson; J J van Dyk; E B van Eden; A M van der Merwe; J A van den Bergh; H C Falkson
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

3.  Program for evaluating drug dissolution kinetics in preformulation.

Authors:  M Nicklasson; A B Magnusson
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

4.  Phase I trial of a new form of an oral administration of VP-16-213.

Authors:  M E Lau; H H Hansen; N I Nissen; H Pedersen
Journal:  Cancer Treat Rep       Date:  1979-03

Review 5.  Review of etoposide.

Authors:  N C Phillips; R D Lauper
Journal:  Clin Pharm       Date:  1983 Mar-Apr

6.  Improved holder for intrinsic dissolution rate studies.

Authors:  J Wood; J Syarto; H Letterman
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

7.  Stability-indicating high-performance liquid chromatography of etoposide at various pH conditions using a reversed-phase octyl column.

Authors:  D Chow; J Shah; J R Chen
Journal:  J Chromatogr       Date:  1987-06-19

Review 8.  Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent.

Authors:  J A Sinkule
Journal:  Pharmacotherapy       Date:  1984 Mar-Apr       Impact factor: 4.705

Review 9.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

  9 in total
  17 in total

1.  In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.

Authors:  N Lowther; R Fox; B Faller; H Nick; Y Jin; T Sergejew; Y Hirschberg; R Oberle; H Donnelly
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Physicochemical characterization of NPC 1161C, a novel antimalarial 8-aminoquinoline, in solution and solid state.

Authors:  Asish Kumar Dutta; Steven P Stodghill; Christy M Wyandt
Journal:  AAPS PharmSciTech       Date:  2010-12-30       Impact factor: 3.246

3.  Effect of particle size of nanospheres and microspheres on the cellular-association and cytotoxicity of paclitaxel in 4T1 cells.

Authors:  Sinjan De; Donald W Miller; Dennis H Robinson
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

Review 4.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Antitumor agents. 125. New 4 beta-benzoylamino derivatives of 4'-O-demethyl-4-desoxypodophyllotoxin and 4 beta-benzoyl derivatives of 4'-O-demethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

Authors:  X M Zhou; Z Q Wang; H X Chen; Y C Cheng; K H Lee
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

Review 6.  Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide.

Authors:  Ishtiyaq Ahmad Najar; Rakesh Kamal Johri
Journal:  J Biosci       Date:  2014-03       Impact factor: 1.826

7.  The construction and characterization of layered double hydroxides as delivery vehicles for podophyllotoxins.

Authors:  Yan Hua Xue; Rui Zhang; Xiao Yu Sun; Shi Long Wang
Journal:  J Mater Sci Mater Med       Date:  2007-08-15       Impact factor: 3.896

8.  Development and evaluation of sustained-release etoposide-loaded poly(ε-caprolactone) implants.

Authors:  Ana Gabriela Reis Solano; Adriana de Fátima Pereira; Flavia Carmo Horta Pinto; Letícia Gonçalves Resende Ferreira; Leandro Augusto de Oliveira Barbosa; Silvia Ligório Fialho; Patrícia Santiago de Oliveira Patricio; Armando da Silva Cunha; Gisele Rodrigues da Silva; Gérson Antônio Pianetti
Journal:  AAPS PharmSciTech       Date:  2013-05-11       Impact factor: 3.246

9.  Stability of the i.v. and oral formulations of etoposide in solution.

Authors:  S P Joel; P I Clark; M L Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Pharmacological attempts to improve the bioavailability of oral etoposide.

Authors:  S P Joel; P I Clark; L Heap; L Webster; S Robbins; H Craft; M L Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.